Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.65 |
| ▸ | HTR1A | P08908 | 6/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.65 |
| ▸ | DRD3 | P35462 | 6/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.65 |
| ▸ | DRD1 | P21728 | 5/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8050972 | 0.98 | LMNA (0.66) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Aminopromazine SCHEMBL25156 | 0.84 | CHRM2 (0.70) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Aminopromazine SCHEMBL30990818 | 0.84 | CHRM2 (0.70) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Aminopromazine SCHEMBL5307944 | 0.83 | CHRM2 (0.68) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Bromide SCHEMBL22588344 | 0.82 | CYP2D6 (0.66) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| SCHEMBL7344075 | 0.81 | CYP2D6 (0.60) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| (S)-Promethazine SCHEMBL2900853 | 0.79 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| SCHEMBL6883388 | 0.79 | CHRM2 (0.67) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Promethazine SCHEMBL26777 | 0.79 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| SCHEMBL6879961 | 0.79 | CHRM2 (0.67) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| EP-0969845-B1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL NV (NL) | 2006-03-01 | — | — | EP | claimed |
| US-6150353-A | USE OF MIRTAZAPINE AND AN ANTIPSYCHOTIC DRUG COMBINATIONS ENHANCES THEEFFECT OF THE ANTIPSYCHOTIC AGENT TO BE USED AND ALLOW BETTER MANAGEMENT OF DRUG RELATED TOXICITY AND SIDE EFFECT | AKZO NOBEL N.V. (NL) | 2000-11-21 | — | — | US | claimed |
| US-6140324-A | ADMINISTERING TACHYKININ ANTAGONIST AND MUSCARINIC ANTAGONIST AND/OR ANTIHISTAMINE, SUCH THAT THEY GIVE EFFECTIVE RELIEF FROM MOTION SICKNESS | MERCK SHARP & DOHME LTD. (GB) | 2000-10-31 | — | — | US | claimed |
| EP-0969845-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | Akzo Nobel N.V. (NL) | 2000-01-12 | — | — | EP | claimed |
| WO-1998043646-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL N.V. (NL) | 1998-10-08 | — | — | WO | claimed |
| WO-1997002824-A1 | USE OF A TACHYKININ ANTAGONIST AND A MUSCARINIC ANTAGONIST AND/OR AN ANTIHISTAMINE TO TREAT MOTION SICKNESS | MERCK SHARP & DOHME LIMITED (GB) | 1997-01-30 | — | — | WO | claimed |
| CN-111246873-B | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnosis and therapy delivery | 加利福尼亚大学董事会 | 2024-03-01 | — | — | CN | disclosed |
| CN-111902143-B | Inhibitors of calcium concentration increase in nerve cells | 东丽株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-117241786-A | Method for preparing dry powder by using film freezing based on suspension | 德克萨斯大学系统董事会 | 2023-12-15 | — | — | CN | disclosed |
| CN-117138051-A | Silica gel material, preparation method thereof, silica gel tube and implant containing silica gel tube | 沈阳药科大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-117017897-A | Implant and method for testing drug release amount thereof | 沈阳药科大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-116808314-A | Silica gel material, preparation method thereof, silica gel tube and implant containing silica gel tube | 沈阳药科大学 | 2023-09-29 | — | — | CN | disclosed |
| WO-2010126953-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20070166364-A1 | Transdermal Therapeutic System | BEIER CORNELIA | 2007-07-19 | — | — | US | disclosed |
| US-7220473-B2 | Storage stability | HEXAL AG (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040047901-A1 | Storage stability | HEXAL AG (DE) | 2004-03-11 | — | — | US | disclosed |
| EP-0173729-B1 | PROCESS FOR SOLUBILIZING ACTIVE PRINCIPLES AND PHARMACEUTICAL COMPOSITIONS THUS OBTAINED | CORBIERE, Jérôme (FR) | 1990-10-17 | — | — | EP | disclosed |
| EP-0173729-A1 | PROCESS FOR SOLUBILIZING ACTIVE PRINCIPLES AND PHARMACEUTICAL COMPOSITIONS THUS OBTAINED. | CORBIERE JEROME | 1986-03-12 | — | — | EP | disclosed |
| WO-1985004106-A1 | PROCESS FOR SOLUBILIZING ACTIVE PRINCIPLES AND PHARMACEUTICAL COMPOSITIONS THUS OBTAINED | CORBIERE JEROME | 1985-09-26 | — | — | WO | disclosed |